#China #Chengdu #Kelun-Biotech #HER2 #Trastuzumab Botidotin

Overview of the Phase III Study Results

A significant advancement in the treatment of HER2-positive breast cancer has been documented through a phase III randomized study comparing the efficacy of Trastuzumab Botidotin against T-DM1. Published in the prestigious Journal of Clinical Oncology (JCO), these results underscore the growing potential of targeted therapies in oncology. The study investigated this novel drug's effectiveness on patients with unresectable or metastatic breast cancer who had undergone prior treatments.

Study Design and Methodology

The trial, completed with a total of 365 patients, was structured as a randomized, open-label multicenter study. The objective was to measure the efficacy and safety profile of Trastuzumab Botidotin in comparison to the well-established T-DM1 treatment. Participants were allocated to receive either Trastuzumab Botidotin or T-DM1, with the primary endpoint focused on progression-free survival (PFS) as evaluated by blinded independent central review (BICR). Secondary metrics included overall survival (OS), objective response rate (ORR), and duration of response (DoR).

Key Findings

Upon reaching the predefined data cutoff on April 26, 2025, with a median follow-up duration of 14.9 months, remarkable differences in efficacy were observed. The median PFS for patients treated with Trastuzumab Botidotin was noted at 11.1 months, compared to Just 4.4 months in the T-DM1 group—this delivered a hazard ratio (HR) of 0.39, indicative of a considerable benefit. Notably, Trastuzumab Botidotin exhibited an ORR of 76.9% versus 53.0% seen with T-DM1, as well as a median DoR difference of 12.2 months against 5.7 months.

Furthermore, although OS data is not yet fully matured, a favorable trend was discerned, suggesting a 38% lower risk of death associated with Trastuzumab Botidotin. Safety assessments revealed a lower incidence of significant adverse effects compared to its counterpart, with interstitial lung disease (ILD) occurring infrequently. The predominant treatment-related adverse events (TRAEs) included ocular issues, which were generally manageable.

Significance in Clinical Oncology

The publication marks a critical milestone in the international academic landscape for HER2-targeted therapies, especially since it's the first phase III trial in China evaluating a HER2 antibody-drug conjugate (ADC) against T-DM1. The findings validate the promising efficacy profile of Trastuzumab Botidotin, reinforcing its safety and tolerability for patients. Given these results, the drug has gained approval from China's National Medical Products Administration (NMPA), presenting itself as a pioneering option for second-line or further treatment for patients battling HER2-positive breast cancer.

Future Directions

As Trastuzumab Botidotin emerges in the market, further studies are already underway. A new multi-center Phase 2 trial has commenced, focusing on further assessing its benefits for patients with HER2-positive, unresectable, or metastatic breast cancer previously treated with topoisomerase inhibitor payload ADCs. Looking ahead, Kelun-Biotech—responsible for the development of Trastuzumab Botidotin—aims to expand its utility within the realm of oncology, with multiple innovative projects currently in different stages of research and development.

About Kelun-Biotech

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates at the forefront of biopharmaceutical innovation, focusing on serious diseases, including solid tumors and autoimmune disorders. With a commitment to global collaboration, Kelun-Biotech aims to address unmet medical needs while aspiring to become a leader in the biological pharmaceuticals market. As the company pivots towards creating impactful treatments, it stands as a testament to the potential of innovative drugs in improving patient outcomes against formidable diseases like cancer.